The Avoca Group Selects Strategic Partner, Sitrof Technologies
Sitrof Technologies
, a provider of IT and document management solutions for the life sciences industry, and
The Avoca Group
, a consulting and research organization specializing in clinical outsourcing and alliance management, today announced a strategic partnership specifically tailored for the life sciences industry.
“The Avoca Group provides comprehensive alliance and relationship management consulting services to the life sciences industry and we are always in search of best-of-breed solutions,” said Avoca President Patricia Leuchten. “By partnering with Sitrof Technologies our clients and Avoca Quality Consortium member companies will benefit as we streamline our processes through the application of the latest technologies available. In addition, as part of the partnership, Avoca and Sitrof will proactively identify ways that technology enablers can support Avoca's mission to help their clients build, measure and manage business relationships in the life sciences area."
Sitrof Technologies’ award-winning solutions have been deployed in dozens of life sciences companies including CROs, IRBs and other life sciences service partners in clinical trials, quality management and regulatory affairs. Founding partners Dan Wheeler and Bryan Reynolds have built a highly successful IT services business helping life sciences companies streamline and automate their processes.
“Unstructured content generation and the need for outsourcing are both growing at tremendous rates within life sciences companies, with no slow down in sight,” said Reynolds. “By working with The Avoca Group and Sitrof Technologies, life sciences companies can be assuredthey are implementing best practices in relationship management and qualitymanagement based on the most up-to-date, validated technologies and Business Process Management (BPM) platforms.”
Related Links:
The Avoca Group Announces Consortium on Quality Management and Oversight
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
